How IgA autoantibody profiles in lupus
A study recently published in the BMJ Journal RMD Open has provided new insights into the immunological landscape of systemic lupus erythematosus (SLE, or lupus) by focusing on IgA isotype autoantibody, a less-studied group of these proteins in lupus. The research, led by Dr Fabien Vincent and carried out by first author Dr Laura Eades during her PhD, was a collaborative effort involving a multidisciplinary team of medical researchers, clinicians and data experts from several leading institutions, including Monash University, Imperial College London and the Garvan Institute of Medical Research.
This study looked at lupus, an autoimmune illness in which the immune system mistakenly attacks healthy tissues and organs. People with lupus often develop autoantibodies, which are proteins that wrongly target the body's own tissues rather than protecting it from infections.
Together, they analysed more than 1,600 IgA autoantibodies in 60 patients with lupus, to help better understand why lupus affects people in different ways. They identified distinct immune patterns linked to different forms of lupus, including kidney disease, and identified several potential new biomarker candidates that may help doctors better diagnose, monitor or personalise care for patients in the future.
This study provides new insights into an understudied part of the immune system in lupus. It suggests that specific IgA autoantibody patterns are linked to important disease features, including lupus kidney disease and blood-related complications. These findings may lead to the development of new biomarkers that help doctors diagnose lupus earlier, identify patients at risk of particular complications and provide more personalised treatment in the future.
The authors hope to raise awareness of lupus and the need for more personalised approaches to lupus care. By highlighting the potential role of IgA autoantibodies as biomarkers, they aim to encourage further research that could help doctors better identify different types of lupus, recognise patients at risk of complications, improve disease monitoring and ultimately improve outcomes for people living with lupus.
Dr Vincent said that lupus is a highly complex autoimmune illness, and no two patients experience it in exactly the same way. “By exploring a less-studied group of autoantibodies, we identified distinct immune signatures linked to different forms of lupus, including kidney disease,” he said. “We hope these findings will contribute to the development of new biomarkers and support future efforts to improve care for people living with lupus."